Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial
- 1 June 2009
- journal article
- clinical trial
- Published by Elsevier in The Lancet Oncology
- Vol. 10 (6) , 549-558
- https://doi.org/10.1016/s1470-2045(09)70109-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasoneSupportive Care in Cancer, 2009
- Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 2008
- Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost ImplicationsJournal of Clinical Oncology, 2005
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index?Emesis (FLIE) with 5-day recallSupportive Care in Cancer, 2003
- Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomitingCancer, 2003
- The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapyAnnals of Oncology, 1997
- Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group StudyOncology, 1995
- Quality of life consequences of chemotherapy-induced emesisQuality of Life Research, 1992
- Serotonin Antagonists: A New Class of Antiemetic AgentsJNCI Journal of the National Cancer Institute, 1991